• Facebook
  • X
  • Instagram
  • Contact Us
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page
Hypercalcemia Indicates Poor Outcomes in Newly Diagnosed Multiple Myeloma (NDMM)

Hypercalcemia Indicates Poor Outcomes in Newly Diagnosed Multiple Myeloma (NDMM)

by MM360 Staff | Nov 19, 2020 | Featured News, Myeloma News

A new study published in Cancer Medicine demonstrates that Hypercalcemia is associated with poor rates of survival in patients with newly diagnosed myeloma (NDMM). The researchers retrospectively evaluated the prognostic impact and mechanism of hypercalcemia in 357...
Accurate Identification of Patients with SMM at Highest Risk of Developing MM Remains Difficult

Accurate Identification of Patients with SMM at Highest Risk of Developing MM Remains Difficult

by MM360 Staff | Nov 19, 2020 | Featured News, Myeloma News

Smoldering multiple myeloma (SMM) is a plasma cell disorder with the potential to evolve to multiple myeloma. Several risk stratification models have been used to identify patients at high risk who may be eleigible for early treaetment. In an article published today...
FDA Lifts Clinical Hold on MELANI-01 Study Evaluating UCARTCS1

FDA Lifts Clinical Hold on MELANI-01 Study Evaluating UCARTCS1

by MM360 Staff | Nov 18, 2020 | Featured News, Myeloma News

Cellectis announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Phase 1 MELANI-01 trial evaluating the UCARTCS1 product candidate for the treatment of patients with relapsed or refractory multiple myeloma (MM). Cellectis worked...
Once-weekly Regimen of Selinexor, Bortezomib, and Dexamethasone Slows Progression of RRMM

Once-weekly Regimen of Selinexor, Bortezomib, and Dexamethasone Slows Progression of RRMM

by MM360 Staff | Nov 14, 2020 | Featured News, Myeloma News

A once-weekly regimen of selinexor, bortezomib, and dexamethasone slows the progression of relapsed or refractory multiple myeloma, according to a study published in the Nov. 14 issue of The Lancet. The results from the BOSTON study demonstrate that the once-weekly...
GSK to Measure Minimal Residual Disease with clonoSEQ, Adaptive Biotechnologies’ next-generation sequencing assay

GSK to Measure Minimal Residual Disease with clonoSEQ, Adaptive Biotechnologies’ next-generation sequencing assay

by MM360 Staff | Nov 11, 2020 | Featured News, Myeloma News

GlaxoSmithKline plc (GSK) to use its clonoSEQ® Assay to assess minimal residual disease (MRD) in GSK’s portfolio of hematology products. MRD is increasingly used as an endpoint in clinical trials, and clonoSEQ has emerged as the premier test to reliably and accurately...
ALLO-715 Phase 1 Data in Relapsed/Refractory Multiple Myeloma to be Presented at ASH

ALLO-715 Phase 1 Data in Relapsed/Refractory Multiple Myeloma to be Presented at ASH

by MM360 Staff | Nov 4, 2020 | Featured News, Myeloma News

Allogene Therapeutics, announced that it will present data on ALLO-715, an anti-BCMA AlloCAR T therapy at the 62nd Annual Meeting of the American Society of Hematology (ASH), taking place virtually December 5 – 8, 2020. The oral presentation will include data on...
« Older Entries
Next Entries »

Recent Content

  • Efficacy and safety of daratumumab for the treatment of refractory/relapsed multiple myeloma. A systematic review of meta-analyses
  • Cell surface marker heterogeneity in human myeloma cell lines for modeling of disease and therapy
  • A systematic review on the epidemiology and treatment options of multiple Myeloma in Asia
  • Blenrep-Based Combo Provides Survival Benefit in Relapsed/Refractory Multiple Myeloma
  • A systematic literature review on clonal evolution events preceding relapse in multiple myeloma
  • Efficacy and safety of teclistamab in relapsed or refractory multiple myeloma: a systematic review and meta-analysis
  • A systematic review and meta-analysis of carfilzomib-associated thrombocytopenia as an adverse event in patients with multiple myeloma
  • Comparing stem cell mobilization with chemotherapy and cytokine (G-CSF) versus cytokine alone in myeloma patients (MOCCCA): a randomized phase II, open-label, non-inferiority trial
  • Triplet regimen extends OS in relapsed or refractory multiple myeloma
  • Allogeneic hematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for multiple myeloma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT
  • Contact Us
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT